Prev Close | 0.00 |
Day Low/High | 0.00 / 0.00 |
52 Wk Low/High | 0.00 / 0.00 |
Prev Close | 0.00 |
Day Low/High | 0.00 / 0.00 |
52 Wk Low/High | 0.00 / 0.00 |
Exchange | NASDAQ |
Div & Yield | N.A. (N.A) |
These four biotech stocks have been moving on some interesting news and clinical results.
The upside may look limited here, but it is not easy to fight.
There really is no such thing as "bad news" right now because there are buyers regardless.
Market has been slow but steady with no overtly negative action.
Buyers don't have much staying power.
We would look to go long VA on a $39 buy-stop using a $34 sell-stop.
When to take profits is a tricky but important decision.
The market seems to be severely discounting DynaVax's chances of approval for its hep-B treatment.
For speculative investors.
We're establishing a new position in Zillow, and making a number of other adjustments.
But the market still has more work to do.
The iShares Transportation Average (IYT) is one to watch.
Focus on buying the dip for IWM.
There's plenty of opportunity despite the low volume.
Forget market chatter, just focus on price.
There has been huge progress in treating this lethal disease.
A bias between neutral and bullish is most appropriate.
Corn is still in a horrific bear market.
I suggest you add CORN to your screen.
Here we go. By Bret Jensen The market is slightly up across the board in the first 30 minutes of trading, and the 10-year Treasury yield is approaching 2.65%. Deckers Outdoor (DECK) is nicely up due to an upgrade at Wells Fargo, which now has price ...
Political squabbling in the U.S. and in Italy has pushed stocks down globally. Achillion Pharma plunges as Apple Beats Coke on branding.
Its been a busy summer for biotech, but the coming weeks will heat up with trials from Biodel, Achillon and Coronado, says Adam Feuerstein, Sr. Columnist at TheStreet.